NCT04656301View on ClinicalTrials.gov

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

November 2, 2022

Study Completion Date

November 2, 2022

Conditions
Body Dysmorphic Disorders
Interventions
DRUG

Psilocybin

A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute

Trial Locations (1)

10032

New York State Psychiatric Institute, 1051 Riverside Drive, New York

Sponsors

Collaborators (1)

COMPASS Pathways
All Listed Sponsors
collaborator

COMPASS Pathways

INDUSTRY

collaborator

University of California, Los Angeles

OTHER

lead

New York State Psychiatric Institute

OTHER